Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-5907
Authors: Krebs, Franziska K.
Trzeciak, Emily R.
Zimmer, Sophia
Özistanbullu, Deniz
Mitzel-Rink, Heidrun
Meissner, Markus
Grabbe, Stephan
Loquai, Carmen
Tüttenberg, Andrea
Title: Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
Online publication date: 12-May-2021
Language: english
Abstract: BACKGROUND Malignant melanoma is an immunogenic skin cancer with an increasing global incidence. Advanced stages of melanoma have poor prognoses. Currently, there are no reliable parameters to predict a patient's response to immune checkpoint inhibitor (ICI) therapy. METHODS This study highlights the relevance of a distinct immune signature in the blood for response to ICI therapy and overall survival (OS). Therefore, the immune cell composition in the peripheral blood of 45 melanoma patients prior to ICI therapy was analyzed by flow cytometry and complete blood count. RESULTS Responders to ICI therapy displayed an abundance of proliferating CD4+ T cells, an increased lymphocyte‐to‐monocyte ratio, a low platelet‐to‐lymphocyte ratio, low levels of CTLA‐4+ Treg, and (arginase 1+) polymorphonuclear myeloid‐derived suppressor cells (PMN‐MDSC). Nevertheless, non‐responders with similar immune cell compositions also benefited from therapy displaying increased long‐term OS. CONCLUSION Our study demonstrated that the observed immune signature in the peripheral blood of melanoma patients prior to treatment could identify responders as well as non‐responders that benefit from ICI immunotherapies.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
DOI: http://doi.org/10.25358/openscience-5907
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC BY
Information on rights of use: https://creativecommons.org/licenses/by/4.0/
Journal: Cancer medicine
10
5
Pages or article number: 1562
1575
Publisher: Wiley
Publisher place: Hoboken, NJ
Issue date: 2021
ISSN: 2045-7634
Publisher URL: https://doi.org/10.1002/cam4.3710
Publisher DOI: 10.1002/cam4.3710
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
krebs_franziska_k.-immune_signatu-20210512105700368.pdf1.29 MBAdobe PDFView/Open